Munalea 30 (Desogestrel, Ethinylestradiol)

Desogestrel, the active ingredient in Munalea 30, is a combined oral contraceptive presented as a tablet for oral use. It works together with ethinylestradiol to prevent pregnancy in women of reproductive age. The formulation belongs to the hormonal contraceptive class and is prescribed for the prevention of unintended pregnancy.

GNH USA supplies Munalea 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through stringent regulatory compliance and reliable logistics across global markets.

Munalea 30, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

- Contraception: prevents ovulation and thereby avoids unintended pregnancy. - Family planning: provides a reliable hormonal method for women seeking birth control. - Menstrual cycle regulation: may help achieve more predictable bleeding patterns. - Cycle control: reduces menstrual cramps associated with hormonal fluctuations. - Hormonal balance: stabilizes estrogen and progesterone levels during the cycle.

Desogestrel/Ethinylestradiol may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Headache: tension or migraine-like pain. - Breast tenderness: discomfort or swelling. - Weight gain: slight increase in body weight. - Irregular bleeding: spotting or changes in menstrual flow. - Mood changes: emotional fluctuations.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Stroke: neurological event due to impaired blood flow. - Myocardial infarction: heart attack. - Severe allergic reaction: anaphylaxis or angioedema. - Liver dysfunction: jaundice or abnormal liver enzymes.

When using Munalea 30, several precautions should be observed to ensure safety.

- Contraindicated in pregnancy: product must not be used by pregnant women. - Avoid smoking over 15 cigarettes per day: increased cardiovascular risk. - Monitor blood pressure regularly: oral contraceptives may elevate BP. - Assess for history of thromboembolic disorders: increased risk of clotting. - Consider liver disease: impaired metabolism may affect drug levels. - Store below 25°C: keep in the original packaging, protect from moisture.

Munalea 30 can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Combined hormonal contraceptives + enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduced efficacy. - Combined hormonal contraceptives + rifampicin: decreased plasma levels. - Combined hormonal contraceptives + certain antiretrovirals (e.g., efavirenz): lowered effectiveness. - Combined hormonal contraceptives + St. John’s wort: increased metabolism. - Combined hormonal contraceptives + additional estrogen therapy: risk of excess estrogen.

Moderate Interactions (Monitor Closely): - Combined hormonal contraceptives + antibiotics (e.g., tetracycline, metronidazole): possible slight reduction in efficacy. - Combined hormonal contraceptives + antihypertensives (e.g., ACE inhibitors): may affect blood pressure control. - Combined hormonal contraceptives + antidepressants (e.g., SSRIs): monitor mood changes. - Combined hormonal contraceptives + diuretics: potential electrolyte imbalance. - Combined hormonal contraceptives + moderately enzyme‑inducing anti‑epileptic drugs: monitor effectiveness.